You are here

TGA Internet site archive

The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.

TGA announcement regarding extension of shelf life of oseltamivir (Tamiflu®)

Media release

12 May 2009

The Therapeutic Goods Administration (TGA) has approved an extension to the shelf life for Tamiflu (oseltamivir) from five to seven years, when stored below 25°C. This extension is effective from 1 May 2009.

The approval to extend the shelf life was based on the submission of data by the product's sponsor demonstrating adequate safety, efficacy and stability of the medicine, when stored under appropriate conditions, for a further two years beyond the original expiry date.

This extension applies to Tamiflu capsules only. The approved shelf lives for Tamiflu bulk powder and powder for suspension remain five years and two years respectively.

Media Contact: Kay McNiece, TGA, 0412 132 585